
The Top Line
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
Latest Episodes
Mapping psychedelics’ commercial summit
Several years after the FDA's high-profile rejection of Lykos Therapeutics’ MDMA candidate for post-traumatic stress disorder, a new wave of developers is nearing the regulatory finish line with experimental psychedelic treatments for mental health conditions. But regulatory approval is, in many ways, just the beginning of a complex journey to market for these companies, should their drugs pass muster with the FDA. In this week’s episode of "The Top Line," Fierce Pharma’s Fraiser Kansteiner sits…
Reducing Protocol Burden to Improve Trial Performance (Sponsored)
Clinical trial teams face a difficult balance: preserve scientific rigor while making protocols feasible for sites and participants. In this sponsored episode of The Top Line, host Kelly Hogan speaks with Metta Anderson, general manager of data analytics and insights at WCG, about how protocol burden affects enrollment timelines and trial performance. Anderson discusses how generative AI and large language models can extract structured information from complex protocol documents, enabling data-d…
Digital Twins: Advancing Clinical Evidence Strategy (Sponsored)
Patient digital twins give life sciences teams a framework for evaluating how an individual patient’s health trajectory could change under different treatments or scenarios. In this sponsored episode of The Top Line, host Kelly Hogan speaks with Nadea Leavitt, a clinical statistician and AI researcher at IQVIA, about the role of digital twins in clinical development and evidence generation. Leavitt explains the patient-specific connection that defines a digital twin, how the approach differs fro…
The promise of molecular gates and what comes next
Gate Bioscience is betting that a decades-old biological mechanism could pave the way for a new class of medicines. The biotech is developing small molecules that selectively block disease-causing proteins from passing through a cellular channel called Sec61, causing them to be degraded before they can do harm. The approach could be particularly promising for diseases of the brain, where traditional biologics face significant delivery challenges. Gate's first publicly disclosed program targets p…
Building a More Resilient Biomanufacturing Supply Network (Sponsored)
Biomanufacturing supply networks must deliver consistency while remaining flexible enough to respond to changing demand, material availability and regional requirements. In this sponsored episode of The Top Line, Irena Luo speaks with Brandon Pence, president and chief operating officer at FUJIFILM Biosciences, about building a more reliable and adaptable global supply network. Pence explains how harmonized quality systems, operating standards and raw material specifications can help manufacturi…
How Smarter Healthcare Environments Improve Patient Experience (Sponsored)
Patient experience is shaped by more than clinical care. It begins with transportation, parking and wayfinding, and continues through check-in, the patient room, diagnostics and follow-up. In this sponsored episode of Podnosis, host Irena Luo speaks with Candace LeVaughn, industry principal of healthcare at Schneider Electric, and Debbie Gregory, principal healthcare innovation consulting at SSR, about designing and operating healthcare environments that better support patients and caregivers. T…
Use Kidney Genetics to Strengthen Clinical Trial Design (Sponsored)
Broad chronic kidney disease labels can obscure distinct biology, complicating patient selection, progression assumptions and treatment-signal interpretation. In this sponsored episode of The Top Line, Will Hurth speaks with Dr. Ronen Schneider, medical director of renal genetics at Natera, about the business and development implications of moving toward genotype-defined kidney disease. Schneider explains how RenasightIQ connects genetic test results with clinical intake data, longitudinal labor…
When China Fits a Global Clinical Development Strategy (Sponsored)
China can play several roles in a global clinical development program, from supporting a capital-efficient proof-of-concept study to contributing evidence within a multiregional clinical trial. In this sponsored episode of The Top Line, Caidya Chief Operating Officer Mike Clay and Vice President of Business Development Jinye Shen join Fierce Life Sciences’ Will Herth to discuss how sponsors can decide when and how to include China. The conversation examines China-only, multiregional and sequence…
There's more than one way to build a biotech
As biotech companies continue to navigate a challenging funding environment, Axiom Biosciences is taking an unconventional approach to raising capital and developing new therapies. The company is pursuing a public listing in Hong Kong, with ambitions to eventually list on the Nasdaq. Meanwhile, it's developing several drug delivery platforms, including a stem cell therapy approach that doesn't rely on genetic modification. In this episode of "The Top Line," Fierce Biotech's Marissa Russo speaks …
When drug development gets personal
For nearly three decades, Jigar Raythatha has helped build biotech companies and bring new medicines to patients. But in 2023, the Third Rock Ventures partner found himself on the other side of drug development when he was diagnosed with a rare form of brain cancer. In a remarkable coincidence, the same day Raythatha underwent the MRI that would lead to his diagnosis, Servier announced positive phase 3 results for a drug targeting his type of cancer. The treatment, now approved as Voranigo, was …
How AI turns field conversations into actionable insights (Sponsored)
Life science field teams are a major source of customer insight, but growing complexity, limited HCP access and expanding omnichannel demands can make it difficult to turn every interaction into action. In this sponsored episode of The Top Line, host Kelly Hogan speaks with Nick Syndercombe, STEM AI lead program director at Inizio Ignite, about how AI can help connect real-world field conversations to coaching, strategic insights and stronger execution. Syndercombe explains how STEM AI was devel…
GSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing
In this week's episode of "The Top Line," we're covering a pair of FDA approvals for GSK, an antibody-drug conjugate pact worth up to $15 billion and the growing role of point-of-care advertising in pharmaceutical marketing. First, we look at GSK's big week, which included FDA approval for Jemperli in certain patients with rectal cancer, offering the possibility of avoiding chemotherapy, radiation and surgery. The company also secured a landmark approval for Hibsago, a chronic hepatitis B treatm…
Inside Teva's Weltruza launch and Novo's GLP-1 strategy
In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new opportunities in the pharmaceutical industry. From Teva's growing portfolio of innovative medicines to Novo's expanding reach in the GLP-1 market, both companies are looking to build on their momentum as they prepare for the next phase of growth. First, Fierce Pharma's Fraiser Kansteiner speaks with Christine Fox, Teva's executive vice president of U.S. commercial and head of it…
The Next Chapter for AI in Clinical Trials [Sponsored]
Clinical AI is moving from systems that predict and summarize toward agents that can help execute parts of a workflow. In this sponsored episode of The Top Line, Will Hurth speaks with Saama’s Ari Srinivasan, chief customer success and growth officer, and Yatesh Midha, associate vice president of product management, about what that evolution could mean for clinical development. The conversation places AgentOS, Saama’s orchestration and governance layer, within a broader shift from disconnected A…
How AI could improve clinical trial decision-making (Sponsored)
What if clinical development teams could evaluate potential trial outcomes before a study reaches patients? In this sponsored episode of The Top Line, host Irena Luo speaks with Raja Shankar, vice president for machine learning within AI and technology solutions at IQVIA, about a foundation model designed specifically for life sciences. Shankar explains why general-purpose models may overlook important relationships in patient and clinical trial data and how post-training on life sciences data c…
How we picked the Fierce 15
What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to discuss what the winners tell us about the state of the sector. In this week’s episode of "The Top Line," the Fierce Biotech editorial team reflects on the process of distilling more than 150 high-quality entries into the final Fierce 15 list. The team discusses how the ambitions of these companies are higher than ever and looks back on some of its conversations with the …
Locking in on pharma’s consumerization trend
With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. Now, the CEO of a buzzy pattern-hair-loss biotech is eyeing opportunities in an evolving market that could expand well beyond his own company. In this week’s episode of "The Top Line," Fierce’s Fraiser Kansteiner chats with Reid Waldman, co-founder and CEO of hair loss-focused biotech Veradermics. With impressive data on its reformulated minoxidil candidate and an upsized IPO earlier thi…
Fierce Pharma Week: A look at the biggest trends, campaigns and conversations
Fierce Pharma Week brought thousands of people to Philadelphia for four days of conversations about pharma marketing, commercialization, medical affairs and communications. In this episode of "The Top Line," Fierce editors share the conversations, trends and moments that stood out from the event. Topics include Genentech’s use of humor and celebrity storytelling to raise awareness of diabetic macular edema, how Novo is navigating the extraordinary attention around GLP-1 drugs, and the growing ro…
Inside the growing world of biopharma prediction markets
Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. But they also create a new set of risks for an industry where employees, researchers, contractors and others may have access to confidential information that could give them an edge. In this episode of “The Top Line,” Fierce Biotech’s Will Maddox talks with David Oliwenstein, a partner at Pillsbury Winthrop Shaw Pittman and former SEC enforcement attorney, about how regulators ma…
Clinical trials reach a new automation inflection point (Sponsored)
Clinical development organizations are facing mounting pressure to do more with increasingly complex protocols, larger data sets and tighter timelines. While automation has improved individual processes, many of the industry's most persistent delays continue to occur between tasks, systems and teams. In this sponsored episode of The Top Line, host Lauren Ledger sits down with Greg Lever, director of AI and Technology Solutions at IQVIA, to discuss why agentic AI is gaining attention across clini…
Podcasts

Montreal Now with Aaron Rand Podcast
CJAD 800

Welcome to the weekly MormonNewsRoundup where Al & Dives ruminate on the great and spacious Beehive!
Mormon News Roundup

The Foreign Affairs Interview
Foreign Affairs Magazine

The Larry Elder Show
The Larry Elder Show

Independent Conversations
Independent Institute

Common Sense with Dr. Ben Carson
Crossover Media